TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group
- Authors' contributions: L.W. performed laboratory studies, interpreted data, and wrote the manuscript. M.V. performed statistical analyses, interpreted data, and wrote the manuscript. T.M. performed laboratory studies and analyzed data. S.C. performed laboratory studies and analyzed data. M.D. performed statistical analysis, interpreted data, and wrote the manuscript. L.S. designed the study, interpreted data, and wrote the manuscript. R.A. conceived the project, designed the study, interpreted data, and wrote the manuscript.
- Conflict of interest: Nothing to declare.
Sinusoidal obstruction syndrome is a complication of therapy for pediatric ALL and may be modified by thiopurine methyltransferase activity as well as by MTHFR genotype. We assessed TPMT *3A, *3B, *3C, and MTHFR C677T and A1298C germline genetic polymorphisms among 351 patients enrolled in the thioguanine treatment arm of CCG-1952 clinical trial. TPMT and MTHFR C677T genotypes were not associated with SOS risk. The combination of MTHFR and TPMT variant genotypes was not associated with SOS risk. These suggest that germline genetic variation in TPMT and MTHFR do not significantly alter SOS risk in patients exposed to thioguanine. Pediatr Blood Cancer 2014;61:2086–2088. © 2014 Wiley Periodicals, Inc.